CAS: 1130067-06-9
Trier par
6 produits concernés.
VU0155069
CAS :Formule :C26H28Cl2N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :499.4321VU0155069
CAS :VU0155069, a selective PLD1 inhibitor (IC50: 46 nM), halts cancer cell migration in transwell assays.Formule :C26H27ClN4O2Degré de pureté :98.32%Couleur et forme :SolidMasse moléculaire :462.97VU-0155069
CAS :VU-0155069 is a small molecule that inhibits fatty acid uptake and metabolism in the kidney. It has been shown to suppress tumor growth in a mouse model of breast cancer by inhibiting fatty acid uptake and metabolism, which reduces the production of proinflammatory molecules. VU-0155069 also inhibits the cation channel CLCN2 in glioma patients, which leads to reduced tumor growth. This drug has shown efficacy in human clinical trials for patients with chronic kidney disease who have not responded to other therapies. VU-0155069 is being investigated as an adjuvant treatment for glioma patients who have already undergone surgery or radiation therapy. VU-0155069 can be used to treat neurodegenerative diseases such as Parkinson's disease by restoring synaptic dysfunction and reducing inflammation.Formule :C26H27ClN4O2Degré de pureté :Min. 95%Masse moléculaire :462.97 g/mol(S)-N-(1-(4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide
CAS :Degré de pureté :98.0%Masse moléculaire :498.158931496
![(S)-N-(1-(4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-nap…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F10%2Fthumb%2FF544995.jpg&w=3840&q=75)
